Quantcast

Latest BioDelivery Sciences International Inc. Stories

2014-07-22 08:31:15

RALEIGH, N.C., July 22, 2014 /PRNewswire/ -- BioDelivery Sciences International, Inc. (BDSI) (NASDAQ: BDSI) announced that its Board of Directors has appointed Charles J. (Chuck) Bramlage and Dr. Barry I. Feinberg as members of the Board. http://photos.prnewswire.com/prnvar/20110217/CL49801LOGO Mr. Bramlage is a veteran pharmaceutical industry executive with extensive experience in marketing, sales and other commercial functions. He is currently the Chief Executive Officer of...

2014-07-07 08:27:32

- Pre-NDA meeting scheduled with FDA in July DUBLIN and RALEIGH, N.C., July 7, 2014 /PRNewswire/ -- Endo Pharmaceuticals Inc., a subsidiary of Endo International plc (NASDAQ: ENDP) (TSX: ENL), and BioDelivery Sciences International, Inc. (NASDAQ: BDSI) announced today positive top-line results from its pivotal Phase III efficacy study of BEMA buprenorphine in opioid-experienced patients. BEMA buprenorphine is being developed for the management of pain severe enough to require...

2014-06-26 08:27:08

Top-line results anticipated by end-of-year RALEIGH, N.C., June 26, 2014 /PRNewswire/ -- BioDelivery Sciences International, Inc. (NASDAQ: BDSI) announced that it has completed enrollment of all patients required for its initial Phase 3 study of Clonidine Topical Gel for the treatment of painful diabetic neuropathy (PDN). http://photos.prnewswire.com/prnvar/20110217/CL49801LOGO The Phase 3 trial is a multicenter, randomized, double-blind, placebo-controlled study to determine the...

2014-06-11 12:26:03

President and CEO Mark A. Sirgo Describes BUNAVAIL(TM) Delivery, Competitive Advantages, Market Size and Patient Need RALEIGH, N.C., June 11, 2014 /PRNewswire/ -- Dr. Mark A. Sirgo, President and Chief Executive Officer of BioDelivery Sciences International, Inc. (NASDAQ: BDSI) was interviewed on Bloomberg TV, TheStreet.com and Business News Network on June 11 regarding BUNAVAIL, BDSI's product for the maintenance treatment of opioid dependence that recently received approval from...

2014-06-10 08:29:27

RALEIGH, N.C., June 10, 2014 /PRNewswire/ -- BioDelivery Sciences International, Inc. (NASDAQ: BDSI) announced that Dr. Mark A. Sirgo, President and Chief Executive Officer of BDSI, will present at two important upcoming healthcare conferences: 34(th) Annual William Blair Growth Stock ConferenceWednesday, June 11, 20143:20 PM Central Time (4:20 PM Eastern Time)Four Seasons Hotel, Chicago, IL Wells Fargo 2014 Healthcare ConferenceTuesday, June 17, 20144:40 PM Eastern...

2014-06-06 16:24:14

First and Only FDA-Approved Buccal Film Formulation of Buprenorphine and Naloxone to Compete in the $1.7 Billion and Growing U.S. Opioid Dependence Market RALEIGH, N.C., June 6, 2014 /PRNewswire/ -- BioDelivery Sciences International, Inc. (BDSI) (NASDAQ: BDSI) received approval of the New Drug Application (NDA) for BUNAVAIL(TM) (buprenorphine and naloxone) buccal film (CIII) from the U.S. Food and Drug Administration (FDA). BUNAVAIL is indicated for the maintenance treatment of...

2014-05-08 20:24:26

BUNAVAIL PDUFA date June 7, 2014; Pre-launch activities underway to support an anticipated late Q3 2014 launch RALEIGH, N.C., May 8, 2014 /PRNewswire/ -- BioDelivery Sciences International, Inc. (NASDAQ: BDSI) announced that it has filed its Quarterly Report on Form 10-Q for the quarter ended March 31, 2014 with the U.S. Securities and Exchange Commission and, in connection therewith, is providing a review of BDSI's recent achievements and an update on business operations and upcoming...

2014-05-08 08:31:55

RALEIGH, N.C., May 8, 2014 /PRNewswire/ -- BioDelivery Sciences International, Inc. (NASDAQ: BDSI) announced that Dr. Mark A. Sirgo, President and Chief Executive Officer of BDSI, will present at the Bank of America Merrill Lynch 2014 Health Care Conference. The presentation is scheduled for Tuesday, May 13, 2014 at 8:40 a.m. Pacific Time (11:40 a.m. Eastern Time) at Encore at Wynn in Las Vegas. The New Drug Application (NDA) for BUNAVAIL for the treatment of opioid dependence is...

2014-05-06 08:33:33

Faster than projected enrollment moves anticipated interim analysis up to third quarter 2014 RALEIGH, N.C., May 6, 2014 /PRNewswire/ -- BioDelivery Sciences International, Inc. (NASDAQ: BDSI) announced that it has randomized more than half of the planned number of patients required for its ongoing initial Phase 3 study of Clonidine Topical Gel, BDSI's proposed treatment for painful diabetic neuropathy (PDN). The intent of the study will be to demonstrate the efficacy and safety of...

2014-04-07 12:32:56

First presentation of detailed BUNAVAIL clinical data scheduled for April 11 and 13, 2014 RALEIGH, N.C., April 7, 2014 /PRNewswire/ -- BioDelivery Sciences International, Inc. (NASDAQ: BDSI) announced that data from clinical studies of BUNAVAIL will be presented at the American Society of Addiction Medicine (ASAM) 45(th) Annual Medical-Scientific Conference, April 10-13, 2014 in Orlando, Florida. Four abstracts will be presented highlighting data from the clinical development...


Word of the Day
holluschickie
  • A 'bachelor seal'; a young male seal which is prevented from mating by its herd's older males (mated bulls defending their territory).
This comes from the Russian word for 'bachelors.'
Related